# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Central Nervous System Lymphoma, Primary

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 42 results.
Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Status: Recruiting
Last Changed: Feb 12, 2020
First Received: Aug 28, 2019
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): Camrelizumab
Locations: Sanbo Brain Hospital Capital Medical University, Beijing, China
Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL)
Status: Not yet recruiting
Last Changed: Feb 05, 2020
First Received: Feb 05, 2020
Disease(s): Primary Central Nervous System Lymphoma (PCNSL)
Intervention(s): Tumor samples and MRI
Locations: Groupe Hospitalier La Pitié Salpêtrière, Paris, France
Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma
Status: Recruiting
Last Changed: Sep 10, 2019
First Received: Sep 10, 2019
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): rituximab in combination with methotrexate, cytarabine and dexamethasone
Locations: Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
Status: Recruiting
Last Changed: May 01, 2020
First Received: Oct 11, 2018
Disease(s): Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Intervention(s): Ibrutinib, Lenalidomide, Rituximab
Locations: Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Memorial Sloan Kettering Commack, Commack, New York, United States
Memorial Sloan Kettering Westchester, Harrison, New York, United States
... and 3 other locations.
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
Status: Recruiting
Last Changed: Jun 12, 2020
First Received: Jul 10, 2018
Disease(s): Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Intervention(s): Ibrutinib, Copanlisib
Locations: Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited protocol Activities), Montvale, New Jersey, United States
Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
... and 3 other locations.
Tisagenlecleucel In Primary CNS Lymphoma
Status: Recruiting
Last Changed: Jan 13, 2020
First Received: Oct 22, 2019
Disease(s): Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma
Intervention(s): Tisagenlecleucel
Locations: Massachusetts General Hospital, Boston, Massachusetts, United States
Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma
Status: Recruiting
Last Changed: Nov 06, 2019
First Received: Dec 07, 2015
Disease(s): Central Nervous System Lymphoma
Intervention(s): Imbruvica
Locations: Hematology Institute, Petah Tikva, Israel
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
Status: Recruiting
Last Changed: Jun 17, 2020
First Received: Jul 30, 2014
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): Isavuconazole, TEDDI, Rituximab, Cytarabine, TEDD, Ibrutinib (Arms 2 and 3), Ibrutinib (Arm 1 - Closed with Amendment G)
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Venetoclax and Obinutuzumab for Relapsed Primary CNS Lymphoma
Status: Recruiting
Last Changed: Apr 02, 2020
First Received: Aug 29, 2019
Disease(s): Primary CNS Lymphoma
Intervention(s): Venetoclax, Obinutuzumab
Locations: Klinikum Stuttgart, Stuttgart, Baden-Württemberg, Germany
[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma
Status: Recruiting
Last Changed: May 24, 2019
First Received: Jun 26, 2018
Disease(s): Primary CNS Lymphoma
Intervention(s): Rituximab, Methotrexate, Cytarabine
Locations: Samsung Medical Center, Seoul, Gangnam-gu,, Korea, Republic of